FDA Clears UltraSPECT's Capability to Cut Cardiac Imaging Time, Radiotracer Dose in Half

 

June 8, 2009

June 8, 2009 – UltraSPECT announced today the addition of the half-dose imaging feature to the capabilities available on the Xpress.Cardiac, its half-time WBR image reconstruction product. This new feature can minimize radiation exposure to patients, maximizing safety for both patients and staff.

With this new, FDA-approved feature, the Xpress.Cardiac now provides nuclear medicine cardiology practitioners with flexibility in both dose and acquisition time management. Depending on the patient and the physician’s preference, the rest/stress studies can be acquired using either half the radiopharmaceutical dose or half the scan time.

UltraSPECT’s half-dose capability has already been routinely utilized in a number of clinical settings in both Europe and in the U.S., with close to a 100 patients already scanned.

UltraSPECT’s Xpress.Cardiac, Xpress3.Cardiac, and Xpress/Xact.Bone products are distributed in the U.S. exclusively by Cardinal Health.

For more information: www.ultraspect.com

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.